Skip to main content
. 2021 Jun 19;90:153635. doi: 10.1016/j.phymed.2021.153635

Fig. 6.

Fig 6

Network pharmacology analysis of RDN. (A) The number of Reduning and acute lung injury targets. (B) The blue circle represents the RDN-related biomarkers; the yellow circle represents the biomarkers of acute lung injury. (C) KEGG pathway enrichment analysis.